Tadalafil Tablet
Product Images NDC 71610-908

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0908 39)

Tadalafil USP 10 mg tablet bottle label, containing 1440 tablets. The label shows storage instructions, manufacturer information as Prinston Laboratories, Charlotte, NC, and labeler as Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The product is for oral use with the NDC 71610-908-39.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, showing its molecular framework with fused ring systems and functional groups, consistent with its known pharmacological profile.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs plotting blood pressure differences (Tadalafil minus Placebo) over time up to 96 hours. The graphs show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with the y-axes labeled as difference in mmHg and x-axes labeled as time in hours.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

A dual-line graph comparing standing and supine systolic blood pressure changes (mmHg) over 24 hours post-dose. One line represents tadalafil 20 mg combined with doxazosin 8 mg, and the other represents placebo with doxazosin 8 mg, showing blood pressure decrease primarily within the first few hours followed by gradual return to baseline.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph showing the change in systolic blood pressure (mmHg) over time (hours) after administration of tadalafil or placebo combined with doxazosin. The x-axis represents time up to 12 hours after dosage, and the y-axis shows systolic blood pressure changes ranging from -20 to 20 mmHg. The graph includes four data series comparing 20 mg tadalafil given at 08:00 and 20:00 hours with placebo controls, each combined with 8 mg doxazosin at 08:00.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The y-axis represents plasma concentration, and the x-axis shows time up to 120 hours, illustrating the pharmacokinetic profiles with error bars for variability.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph showing change from baseline in IPSS total score over 12 weeks of treatment. It compares Tadalafil tablets 5 mg and placebo, indicating greater improvement with Tadalafil as shown by a larger decrease in IPSS score. Data points are marked for weeks 0, 4, 8, and 12.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

Line graph comparing the change from baseline in IPSS total score over 12 weeks between tadalafil 5 mg tablets and placebo. The x-axis shows treatment duration in weeks, and the y-axis represents change from baseline. The tadalafil group shows a greater decrease in score than placebo, with statistical significance indicated at week 4 and week 12.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph comparing the LS mean change from baseline over 26 weeks of therapy for Tadalafil/Finasteride and Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows LS mean change from baseline. Data points show greater decreases for Tadalafil/Finasteride versus Placebo/Finasteride, with indicated statistical significance (p<0.001 and p<0.05) at various points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing change from baseline in IPSS total score over treatment duration in weeks for tadalafil tablets 5 mg versus placebo. The graph shows data points at 0, 2, 4, 8, and 12 weeks, with tadalafil demonstrating a greater decrease in score compared to placebo, and a statistical significance indicated at 12 weeks (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.